Keyhole limpet hemocyanin conjugate vaccines against cancer: The Memorial Sloan Kettering experience

Journal of Cancer Research and Clinical Oncology

Volumn 127, Issue SUPPL. 2, 2001, Pages

  Musselli, Cristina ^a   Livingston, Philip O ^a   Ragupathi, Govindaswami ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15 3 ANTIGEN; CA 15-3 ANTIGEN; CANCER VACCINE; GANGLIOSIDE; HEMOCYANIN; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; TUMOR ANTIGEN; VACCINE;

ARTICLE; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; NEOPLASM; T LYMPHOCYTE; VACCINATION;

ANTIGENS, NEOPLASM; CA-15-3 ANTIGEN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; GANGLIOSIDES; HEMOCYANIN; HUMAN; NEOPLASMS; VACCINATION; VACCINES, CONJUGATE;

EID: 0035489696     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01470995     Document Type: Article

References (52)

1. Barrat-Boyes S (1996) Making the most of mucin: a novel target for immunotherapy. Cancer Immunol Immunother 43: 142-151
2. Bilodeau MT, Park TK, Hu S, Randolph JT, Danishefsky SJ, Livingston PO, Zhang S (1995) Total synthesis of a human breast tumor-associated antigen. J Am Chem Soc 117: 7840-7841
3. Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Kannagi R, Hakomori S (1984) Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBrI expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem 259: 14773-14777
4. Chapman PB, Morrisey D, Panageas KS, Williams L, Lewis JJ, Israel RJ, Hamilton WB, Livingston PO (2000) Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin Cancer Res 6: 4658-4662
5. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO (2000) Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 6: 874-879
6. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA (1987) Ganglioside GD2-specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 1430-1440
7. Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC (1999) Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 5: 2773-2779
8. Ehrlich P (1909) Uber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5: 273-290
9. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO (2000) Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6: 1693-1701
10. Gilewski T, Ragupathi G, Williams LJ, Musselli C, Zhang XF, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, Livingston PO, Danishefsky SJ (2001) Immunization of metastatic breast cancer patients with a fully synthetic Globo H conjugate: a phase I trial. Proc Natl Acad Sci USA 98: 3270-3275
11. Gorer P (1956) Some recent work on tumor immunity. Adv Cancer Res 4: 149-186
12. Helling F, Livingston PO (1994) Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin. Mol Chem Neuropathol 21: 299-309
13. Helling F, Shang A, Calves M, Zhang S, Ren S, Yu RK, Oettgen HF, Livingston PO (1994) GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 54: 197-203
14. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55: 2783-2788
15. Hirschowitz EA, Leonard S, Song W, Ferris B, Leopold PL, Lewis JJ, Bowne WB, Wang S, Houghton AN, Crystal RG (1998) Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther 5: 975-983
16. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242-1246
17. Irie RF, Matsuki T, Morton DL (1989) Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1: 786-787
18. Irie RF, Morton DL (1986) Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83: 8694-8698
19. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66: 249-254
20. Kannagi R, Levery SB, Ishigami F, Hakomori S, Shevinsky LH, Knowles BB, Solter D (1983) New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. J Biol Chem 258: 8934-8942
21. Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO (1999) Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 18: 597-603
22. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, Marciani D (1994) Phase 1 trial of immunolog-ical adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12: 1275-1280
23. Livingston PO, Albino AP, Chung TJ, Real FX, Houghton AN, Oettgen HF, Old LJ (1985) Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic-cultured melanoma cells. Cancer 55: 713-720
24. Livingston PO, Calves MJ, Natoli EJ (1987) Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J Immunol 138: 1524-1529
25. Livingston PO, DeLeo AB, Jones M, Oettgen HF (1983) Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective. J Immunol 131: 2601-2605
26. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ (1987) Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84: 2911-2915
27. Livingston PO, Ragupathi G (1997) Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 45: 10-19
28. Livingston PO, Takeyama H, Pollack MS, Houghton AN, Albino A, Pinsky CM, Oettgen HF, Old LJ (1983) Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer 31: 567-575
29. Livingston PO, Watanabe T, Shiku H, Houghton AN, Albino A, Takahashi T, Resnick LA, Michitsch R, Pinsky CM, Oettgen HF, Old LJ (1982) Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells. Int J Cancer 30: 413-422
30. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, et al (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12: 1036-1044
31. Livingston PO, Zhang S, Lloyd KO (1997) Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother 45: 1-9
32. Livingston PO, Zhang S, Adluri S, Yao TJ, Graeber L, Ragupathi G, Helling H, Fleisher M (1997) Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother 43: 324-330
33. Menard S, Tagliabue E, Canevari S, Fossati G, Colnaghi MI (1983) Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res 43: 1295-1300
34. Old LJ, Boyse EA, Clarke DA, Carswell EA (1962) Antigenic properties of chemically induced tumors. Ann NY Acad Sci 101: 80-106
35. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85: 659-666
36. Ragupathi G, Slovin SF, Adluri S, Sames D, Kim IJ, Kim HM, Spassova M, Bornmann WG, Lloyd KO, Scher HI, Livingston PO, Danishefsky SJ (1999) A fully synthetic Globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle. Angew Chem Int Ed 38: 563-566
37. Ragupathi GPT, Zhang S, Kim IJ, Graber L, Adluri S, Lloyd KO, Danishefsky SJ, Livingston PO (1997) Immunization of mice with a fully synthetic Globo H antigen results in antibodies against human cancer cells: a combined chemical-immunological approach to the fashioning of an anticancer vaccine. Angew Chem Int Ed Engl 36: 125-128
38. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343: 1177-1183
39. Ritter G, Boosfeld E, Adluri R, Calves M, Oettgen HF, Old LJ, Livingston P (1991) Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 48: 379-385
40. Ross HM, Weber LW, Wang S, Piskun G, Dyall R, Song P, Takechi Y, Nikolic-Zugic J, Houghton AN, Lewis JJ (1997) Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res 3: 2191-2196
41. Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W, Spassova M, Zatorski A, Spriggs D, Aghajanian C, Soignet S, Peyton M, O'Flaherty C, Curtin J, Lloyd KO (2000) Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 87: 79-85
42. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, et al (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52: 4342-4347
43. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI (1999) Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic Globo H hexasaccharide conjugate in man. Proc Natl Acad Sci USA 96: 5710-5715
44. Snijdewint FGM, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Kenemas P (2001) Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Cancer Immunol Immunother 48: 47-55
45. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL (1985) Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35: 607-612
46. Woglom W (1929) Immunity to transplantable tumors. Cancer Rev 4: 129-214
47. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO (1998) Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 58: 2844-2849
48. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 73: 42-49
49. Zhang S, Graeber LA, Helling F, Ragupathi G, Adluri S, Lloyd KO, Livingston PO (1996) Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 56: 3315-3319
50. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO (1998) Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res 4: 2669-2676
51. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 73: 50-56
52. Musselli G, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO (2001) Re-evaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer (in press)